Annals of Thoracic Medicine
CASE REPORT
Year
: 2017  |  Volume : 12  |  Issue : 4  |  Page : 294--297

Rituximab treatment in patients with systemic sclerosis and interstitial lung disease


Abdel Gaffar A Mohammed, Ammar Alshihre, Ibrahim Abdulrazag Al-Homood 
 Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA

Correspondence Address:
Ibrahim Abdulrazag Al-Homood
Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, P. O. Box: 59046, Riyadh 11525
KSA

There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide for the treatment of interstitial lung diseases (ILDs) associated with systemic sclerosis (SSc). However, no report has addressed its efficacy in Saudi patients with SSc-ILD. To assess the efficacy of RTX treatment in Saudi patients with SSc-ILD, hospital records were reviewed between 2013 and 2016. Four female patients received at least 4 cycles of RTX (I cycle, consisting of two infusions of 1000 mg 2 weeks apart). Pulmonary function tests (PFTs) and chest high-resolution computed tomography (HRCT) were performed before and after treatment to assess the response. HRCT revealed improvement in one patient, stable disease in two patients, and worsening in one patient. Moreover, RTX prevented the further decline of forced vital capacity significantly in PFT. These results provide further evidence that RTX is an effective treatment for SSc-ILD.


How to cite this article:
Mohammed AA, Alshihre A, Al-Homood IA. Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.Ann Thorac Med 2017;12:294-297


How to cite this URL:
Mohammed AA, Alshihre A, Al-Homood IA. Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. Ann Thorac Med [serial online] 2017 [cited 2020 May 26 ];12:294-297
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2017;volume=12;issue=4;spage=294;epage=297;aulast=Mohammed;type=0